Navigation Links
NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Date:10/25/2007

ential competition from approved drugs or drugs under development that may be safe and effective for the same indication as that targeted by NKTR-102, and (v) the company's patent applications for NKTR-102 may fail to issue; patents that have issued may not be enforceable; or unanticipated intellectual property licenses from third parties may be required in the future. Other important risks and uncertainties are detailed in the company's reports and other filings with the SEC including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise. No information regarding or presented at the scientific meetings referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release.

Contacts: Tim Warner (650) 283-4915 or twarner@nektar.com

Stephan Herrera (415) 488-7699 or sherrera@nektar.com

Jennifer Ruddock (650) 631-4954 or jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Reportlinker.com announces that ... its catalogue: Portugal Pharmaceuticals and ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes 3 ... Faster-than-expected economic growth last quarter has led us ... upwards. As forecast previously, BMI expects ...
(Date:7/28/2014)... Va. , July 28, 2014  Serco ... services, announced the Company has been awarded a ... Support Command (NEMSCOM) and its Deployable Medical Systems.  ... enable medical personnel to provide world-class healthcare to ... operating environment across the globe. The five year ...
(Date:7/28/2014)... 2014  VigeneTech, Inc, in collaboration with BioLegend, ... Analysis Software, an OEM software solution for analysis ... and offers varieties of bead-based multi-analyte immunoassay products ... of VigeneTech,s data analysis software, FCS data files ... reported LEGENDplex™ software is a ...
Breaking Medicine Technology:Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2
... VANCOUVER, Oct. 7 /PRNewswire-FirstCall/ - Burcon NutraScience,Corporation ... and,Supertein(TM) canola protein isolates are GRAS (Generally ... a variety of food and beverage,applications. The ... evaluation by a panel of qualified experts ...
... study of adults, VYVANSE taken once-daily significantly,improved the ... Oct. 7 Shire plc (LSE: SHP,Nasdaq: SHPGY), ... study published in the September issue of the ... Deficit Hyperactivity Disorder (ADHD) symptoms in adults within,the ...
Cached Medicine Technology:Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6
(Date:7/29/2014)... July 29, 2014 Guests at Napa Valley's ... indulged in a new sleep experience. The top of each ... Peacock Alley. , These expertly crafted, 100% Egyptian cotton ... from a distance, yet upon closer look, words are woven ... relax, sleep and breathe. , Intentional breathing and ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 In its ... offers treatment programs and believes that having family close ... big difference in whether or not the process is ... myths. , “It’s difficult to estimate just how damaging ... Rehabilitation’s CEO Per Wickstrom . “Not only do ...
(Date:7/29/2014)... 29, 2014 Launched in 2012 by ... surpassed 20,000 hangovers earlier this year at its Vegas ... expansion and the publication of research data related to ... practice. , The only licensed medical practice dedicated to ... launched in 2012 and treated thousands of patients within ...
(Date:7/29/2014)... 29, 2014 Ticketability.com has reduced the cost ... been selling at lower prices on the secure website. Customers ... further discount on tickets that are priced lower every day. ... tickets available at Ticketability.com. , Theatergoers know that attending an ... find Phantom of the Opera tickets for sale that are ...
(Date:7/28/2014)... July 29, 2014 Treat skin to a ... Sublime Beauty®. , Today and tomorrow only (while supplies last), ... "The cleanser is ideal for two specific users: , 1) ... unclogged and bacteria free, and , 2) aging skin to ... says Kathy Heshelow, founder of Sublime Beauty®. , Those with ...
Breaking Medicine News(10 mins):Health News:Auberge Du Soleil Offers INTENTIONS™ by Peacock Alley on Guests' Beds Providing a Unique Sleep Experience 2Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 2Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 3Health News:Hangover Heaven Surpasses 20,000 Hangovers 2Health News:Hangover Heaven Surpasses 20,000 Hangovers 3Health News:Phantom of the Opera Tickets for Sale: Ticketability.com Delights Customers with Phantom of the Opera Theatre Tickets While Seats Last 2Health News:Clear, Clean Skin With the New Salicylic Wash from Sublime Beauty®; Enlivens Skin, Unclogs Pores 2
... Ten outstanding clinical research projects from institutions around the ... Research Forum Top 10 Clinical Research Achievement Awards. The ... that results from the nation,s investment in clinical research ... hail from Baylor College of Medicine, the Cleveland Clinic ...
... , WEDNESDAY, April 18 (HealthDay News) -- ... adults, risk of being hospitalized for lung and heart ... Harvard School of Public Health researchers compared air-quality data ... 65 and older admitted to 3,000 New England hospitals ...
... 17 (HealthDay News) -- Pregnant women who are overweight ... for pregnancy complications, a new study shows. These women ... normal blood sugar or those with gestational diabetes and normal ... pregnant women who are obese or have gestational diabetes, and ...
... , TUESDAY, April 17 (HealthDay News) -- A new study ... new kind of radiation treatment, in patients with prostate cancer. ... radiation therapy were more likely to suffer from gastrointestinal side ... be any extra benefit for those who got proton therapy. ...
... , TUESDAY, April 17 (HealthDay News) -- Mothers with ... according to a new study. Pennsylvania State University researchers ... the ages of 1 month and 2 years over 7 ... mothers and their infants, quality of sleep. Greater amounts ...
... HealthDay Reporter , TUESDAY, April 17 (HealthDay News) ... cells led to a nearly 50 percent improvement in survival ... that claimed the life of U.S. Sen. Edward Kennedy, a ... about 40 patients with recurrent glioblastoma -- an aggressive brain ...
Cached Medicine News:Health News:Awards celebrate clinical research that can improve health and alleviate suffering 2Health News:Awards celebrate clinical research that can improve health and alleviate suffering 3Health News:More Smog Might Mean More Hospitalizations 2Health News:Overweight Pregnant Women at Higher Risk for Complications 2Health News:Study Casts Doubt on Value of Pricey Prostate Cancer Therapy 2Health News:Study Casts Doubt on Value of Pricey Prostate Cancer Therapy 3Health News:Depressed Moms May Hinder Babies' Sleep 2Health News:Brain Tumor Vaccine Shows Promise in Early Trial 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: